Northwest Bio raises $27M; Australian biotech Innate Immunotherapeutics pitches IPO;

@FierceBiotech: What would a Teva buyout mean for its R&D operation? Story | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline dispatching R&D teams to new satellites in Cambridge, San Diego. Story | Follow @JohnCFierce

@DamianFierce: Sorin's expecting as much as 10% annual growth by 2018. Story | Follow @DamianFierce

@EmilyMFierce: Malaria cases soar in former rebel stronghold of Rutshuru, DRC. More | Follow @EmilyMFierce

> Northwest Biotherapeutics has raised $27 million from a secondary offering. Story

> Australia's Innate Immunotherapeutics is planning to raise A$12 million in an IPO, selling shares at A20 cents a share. The money will be earmarked for a mid-stage study of a new multiple sclerosis drug. News

Medical Device News

@FierceMedDev: 23andMe digs in as FDA wants test off the market. Story | Follow @FierceMedDev

@MarkHFierce: Please check out our latest issue of FierceDiagnostics, with lots of great industry news. Issue | Follow @MarkHFierce

> Cardiovascular Systems bags $102M for artery-clearing Diamondback 360 device. Story

> Swiss team's anti-obesity hormone implant poses Lap-Band challenge. News

> Medtronic's Ishrak: Day-to-day business takes precedence over device tax angst. More

Pharma News

@FiercePharma: Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth. Yesterday's story | Follow @FiercePharma

@EricPFierce: Finally, something that Teva can crow about. Treanda gets orphan status, extending its exclusivity. News | Follow @EricPFierce

@CarlyHFierce: Our annual Top Women in Biotech report is live! Special report | Follow @CarlyHFierce

> FDA bans second Wockhardt plant. News

> Adcock Ingram pleads merger essential for survival. Story

> Administration lauds Medicare drug discounts and wants more, more, more. Article

Drug Delivery News

> Study: Natural nanomaterials could support biodegradable drug delivery. Story

> Alnylam pockets $7M from Genzyme as RNAi program hums along. Article

> Aptar Pharma readies auto-injectable drug delivery tech. Report

> Focal Therapeutics' 3-D tissue marker for targeted cancer therapy reaches milestone. Story

> Arrowhead submits PhIIa application for hep B RNAi candidate. Article

> Supramolecular gel scaffold may support bone drug delivery. Item

Diagnostics News

> Veracyte boosts Dx revenue as CEO Anderson celebrates successful IPO. Story

> Canadian team relies on synchrotron to develop better prostate cancer Dx. Article

> In 23andMe's tussle with the FDA, 'diagnostic' is a contentious word. Story

> Oxford Immunotec, a TB Dx developer, performs well in its Nasdaq debut. Report

> Myriad ups companion Dx focus with BioMarin cancer drug collaboration. News

> BioMérieux team touts development of quicker sepsis Dx approach. Item

Biomarkers News

> Blood biomarker points to post-concussion cognitive problems. Report

> Regulus snags milestone in MS biomarker deal with Biogen. News

> Protein C4d linked to higher mortality rates in lung cancer patients. Story

> Women who test negative for BRCA mutation may still have higher breast cancer risk. Article

> Chemical fingerprint points to a likely biomarker for 'fast' form of Parkinson's. More

> Gentris opens biomarker shop in Shanghai. Item

Vaccines News

> FDA approves GSK's adjuvanted bird flu vaccine for stockpile. Report

> Novartis struggling to find vaccine acquisition targets for $5B war chest. Article

> Ranbaxy reportedly ready to sell vaccine unit. More

> Sanofi hunting for bolt-on vaccine deals. Story

> Value of Pentagon-backed vaccine plant questioned. News

> GAVI adds support for inactivated polio vaccine. Item

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.